Sign up to save your podcasts
Or
Share Pathophysiology and Clinical Features of TTR Cardiac Amyloidosis: No Longer a "Rare" Disease and Still Underdiagnosed
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Pathophysiology and Clinical Features of TTR Cardiac Amyloidosis: No Longer a "Rare" Disease and Still Underdiagnosed
Health Care Practitioners (HCPs) have a pivotal role in ensuring the right patients get the right treatment. Patients living with ATTR-CM have new treatment options that have recently become available. In order to accurately diagnose and treat symptoms unique to the ATTR-CM patient, HCPs need to be aware of the application of guideline-based systematic, multimodal imaging and clinical diagnostics related to ATTR-CM. This podcast will highlight the latest terminology, treatments and guidelines for this no longer rare disease.
Claim CE and MOC at https://bit.ly/ATTR-CM_series
View all episodes
By American Heart Association
5
44 ratings
Health Care Practitioners (HCPs) have a pivotal role in ensuring the right patients get the right treatment. Patients living with ATTR-CM have new treatment options that have recently become available. In order to accurately diagnose and treat symptoms unique to the ATTR-CM patient, HCPs need to be aware of the application of guideline-based systematic, multimodal imaging and clinical diagnostics related to ATTR-CM. This podcast will highlight the latest terminology, treatments and guidelines for this no longer rare disease.
Claim CE and MOC at https://bit.ly/ATTR-CM_series
More shows like Closing Knowledge Gaps in Transthyretin Cardiomyopathy (ATTR-CM)
View all
The NACE Clinical Highlights Show
21 Listeners